An update from Oragenics ( (OGEN) ) is now available.
On September 19, 2024, the Compensation Committee and Board of Directors of a company awarded immediate vesting stock options to key executives, with the President and CFO receiving 100,000 and 80,000 shares respectively, under the company’s Equity Incentive Plan. Additionally, the company announced the rescheduling of its 2023 Annual Meeting of Shareholders to December 11, 2024, and set a new October 20, 2024 deadline for shareholders to submit proposals for inclusion in the proxy statement.
See more insights into OGEN stock on TipRanks’ Stock Analysis page.
